Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIVJoel E. Gallant, Andrew Cheng, José Ramón Arribas et al.|New England Journal of Medicine|2006Cited by 886
Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical TrialAndrew Zolopa, Andrew Cheng, Brian P. Kearney et al.|The Journal of Infectious Diseases|2010Cited by 114
A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected AdolescentsMarinella Della Negra, Martin S. Rhee, Sarah Arterburn et al.|The Pediatric Infectious Disease Journal|2012Cited by 24
A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic SuppressionXavier Sáez‐Llorens, Martin S. Rhee, Andrew Cheng et al.|The Pediatric Infectious Disease Journal|2014Cited by 19